Psoriasis is a genetically determined chronic inflammatory and immunologically mediated disease. At an early age, the presentation of psoriasis may be atypical. Among all types of childhood psoriasis, plaque type is the most common. In this article, we report our data analysis on the main clinical aspects of childhood psoriasis, its onset, risk factors, demographics and therapeutic options.
Introduction
Psoriasis is a genetically determined chronic inflammatory disorder seen in 3.5% of US population (Kurd and Gelfand, 2009) . The incidence in Saudi Arabia has not been precisely defined. It is mainly classified into two age groups: childhood psoriasis that develops below the age of 18 years and adulthood psoriasis that develops after the age of 18 years. Childhood psoriasis is broadly sub-classified into three age groups: infantile psoriasis (onset within the first year of age), pediatric psoriasis and pediatric psoriasis with psoriatic arthritis (Silverberg, 2009 ). Moreover, Congenital psoriasis (psoriasis since birth), a distinct entity of psoriasis associated with lower prevalence of family history, different pattern of anatomic involvement, higher fraction of erythrodermic, pustular or linear subtypes and poor prognosis has been described. It has been suggested that congenital psoriasis should be considered in the category of erythematous, scaly, or pustular eruptions in the newborn (Lehman and Rahil, 2008) . The aim of this article is to look over the clinical aspects, risk factors and therapeutic options of childhood psoriasis in Saudi patients.
Demographics and onset of the disease
In this study a total of 36 patients with childhood psoriasis were evaluated at the dermatology out-patient clinic in the college of medicine at King Saud University during the period from April 2002 to June 2007. The age of patients ranged from 8 months to 18 years (mean = 11.3 years). The mean duration of disease was 3.04 years. Male patients were 15 (41.67%) and females were 21 (51.33%) (see Table 1 ). The incidence of childhood psoriasis is unknown (Marcoux and Prost, 2002) , but it has been reported that 10% of all cases occurred before the age of 10 years and 2% at less than 2 years of age . The differences of the onset between females and males have varied from region to region (Morris et al., 2001) . In a study from India, the age of onset of the disease ranged from 4 days to 14 years. The mean age of onset in boys was 8.1 ± 2.1 years and in girls was 9.3 ± 2.3 years. (Kumar et al., 2004) . In another report from china, a study was carried out in 277 childhood psoriatic patients where the mean age of onset was found to be 11 years. The male: female ratio was 1:1.13. The median age of onset of disease was 10 years (Fan et al., 2007) . Furthermore, a population based study was performed in USA to assess the incidence of childhood psoriasis which revealed that the annual incidence was 40.8 per 100,000. Authors concluded that the incidence of pediatric psoriasis increased with age and both males and females suffer equally (Tollefson et al., 2010) . In a retrospective analysis from Turkey, 61 children with psoriasis under age of 18 years were evaluated. Twenty three (37.70%) were males and 38 (62.30%) were females. The mean age of patients was 9.28 ± 4.02% for females and 11.18 ± 3.85% for males. The mean age of onset of the disease in females was 6.81 ± 4.11 years and 7.03 ± 4.28 years in males (Seyhan et al., 2006) .
Risk factors
In a recent report, there was no evidence to support that getting affected by psoriasis before the age of 18 years influences disease activity in later life or type of treatments used (Jager and Jong, 2010) . The association of childhood obesity and psoriasis is of significance. A study was conducted to observe the influence of obesity on childhood psoriasis, it was concluded that being overweight is an important risk factor for the onset of childhood psoriasis (Boccardi and Menni, 2009) . It is suggested that psoriasis should be added to the adverse consequences of childhood obesity (Naldi et al., 1996) . Seyhan et al, from Turkey found that in most of their 61 patients the triggering factors were respiratory tract infections (14.8%) and positive throat culture for group A-beta hemolytic streptococci (21.3%). Also, the frequency of emotional stress and psychiatric morbidity was 54% and 9.8%, respectively. It is suggested that stress and upper respiratory tract infections are the most important triggering factors in childhood and adult psoriasis. They also reported a positive family history in 14 cases (23%) (Seyhan et al., 2006) .
Apart from positive family history in one third of our patients, we did not find any other significant associated factors. This might be explained by the small number of patients in our study.
Clinical patterns
In our study, all patients were diagnosed based on clinical findings. Of the 36 patients, 24 (66.67%) had generalized plaque type psoriasis, 8 (22.2%) had guttate psoriasis, 4 (11.1%) had mixed plaque type and guttate psoriasis (see Fig. 1 ), 6 (16.67%) had localized plaque type (on elbows and knees), 4 (11.11%) had palmoplanter psoriasis and 1 (2.77%) had scalp psoriasis. Among those, one patient had congenital psoriasis (see Table 1 ).
Most children with psoriasis manifest with the plaque type disease (68.6%) in similar patterns to adult patients, with lesions being localized to the scalp, post auricular region, elbows, and knees. Guttate disease is more common in pediatric than in adult patients. It was present in 28.9% of 277 children in a Chinese survey. Other patterns in childhood psoriasis include erythroderma (1.4%), pustular disease including palmoplantar pustular psoriasis (1.1%), and mucosal glossitis (1.1%) (Fan et al., 2007) . Another study has shown that the most frequent clinical type of childhood psoriasis is plaque type in 1302 patients (68.1%), followed by guttate psoriasis in 727 patients (38.0%). Erythrodermic psoriasis and pustular psoriasis were only seen in 7.3% and 5.0% of patients, respectively (Jager and Jong, 2010). Though generalized pustular psoriasis in children is uncommon, it may present as a severe and potentially life-threatening disorder. Four clinical patterns of pustular psoriasis have been described in children: generalized pustular psoriasis, annular pustular psoriasis, exanthematous pustular psoriasis, and localized pustular psoriasis. Mixed variants of these patterns are also possible. Generalized pustular psoriasis has been reported in a 6-weekold infant (Chao et al., 2009) . In regard to congenital psoriasis, erythrodermic and pustular variants are common presentations (Lehners-Weber et al., 1996; Al-Fouzan et al., 1990; Lerner and Lerner, 1972; Henriksen and Zachariae, 1972) .
Therapy
Topical treatment is the first line therapy in childhood psoriasis for a limited disease. In a more severe disease, systemic therapy and phototherapy are considered to control the disease. Well-designed studies on systemic therapeutic modalities for psoriasis in pediatric age group are meager and children are treated with the support of data extrapolated from those in adults .
Topical treatment
There are various agents frequently used as topical therapies for childhood psoriasis. Topical corticosteroids are usually prescribed. Mild forms of topical corticosteroids are used for the face, whereas, moderate to potent forms are used for the body and scalp. More than 40% of our patients were treated by either topical corticosteroids or calcipotriene. Topical Calcipotriene was proved to be efficacious in childhood psoriasis treatment in 43 children (Oranje et al., 1997) . Anthralin 1% is rarely used in childhood psoriasis because of localized irritation (Farber and Nall, 1999) . Other topical agents described in the treatment of childhood psoriasis are topical calcineurin inhibitors, tacrolimus 0.3% ointment, and pimecrolimus 1% cream (Stefanakiet al., 2010) .
Phototherapy
Phototherapy is considered a safe and effective treatment for children. Generalized or hand-foot therapy, either narrowband ultraviolet-B (NB-UVB), broadband UVB (BB-UVB) or psoralen and UVA (PUVA) can be used. More than 60% of our patients were treated with NB-UVB and satisfactory results were observed (see Table 1 ). In one report, 12 weeks treatment with NB-UVB, PASI 90 was achieved in 60% of patients, however, 10% had less than 50% improvement (Jain et al., 2007) . A series of 113 children were treated by various phototherapy methods. Positive response was observed in 92.9% of psoriatic patients treated by NB-UVB, in 83.3% of those treated with PUVA and in 93.3% of those treated with BB-UVB (Ersoy-Evans et al., 2008) . NB-UVB and PUVA therapies have shown satisfactory results in treating childhood guttate and plaque psoriasis as marked improvement was found in 88% of 25 patients treated with these two modalities (Al-fouzan and Nanda, 1995) . In another study conducted on 35 patients of childhood psoriasis, clearance of disease was found in 63% of cases (Jury et al., 2006) . Only few cases are reported to develop erythema and anxiety during phototherapy, otherwise, treatment is being well tolerated (Tay et al., 1996) . From our experience, phototherapy is considered safe and effective treatment of childhood psoriasis where NB-UVB is favored over PUVA due to increased safety profile and convenience for patients. During Phototherapy, Our patients encountered tanning effect, pruritus and dryness that might be aggravated by local climate nature. In our data no single case of skin cancer was reported over 10 year experience with phototherapy. Although phototherapy is a simple, safe and effective treatment, both children and their parents must be educated for the possible adverse effects and the associated hazards of overexposure.
Oral antibiotics
Multiple studies implicate subclinical or recurrent streptococcal infection as a trigger or maintenance factor in the pathogenesis of psoriasis in children. In one study reviewing studies and reports examining this particular relationship concluded that the percentage of psoriasis patients who experienced disease clearance with antibiotic therapy ranged from 0% to 55%, with no patients experiencing disease worsening during treatment. The available evidence does not demonstrate the efficacy of antibiotic therapy in the treatment of childhood psoriasis. Because these treatments are relatively benign compared to other treatments for severe psoriasis, the use of antibiotic therapy may still be worth considering, especially for those patients with recurrent streptococcal infections that seem to trigger or maintain their skin disease (Wilson et al., 2003) . A controlled study revealed mixed results of oral antibiotics therapy in childhood psoriasis (Dogan et al., 2008) . In our experience the response to oral antibiotics in children with psoriasis was variable with majority being none responsive.
Systemic treatment
Systemic treatment is the ultimate option in severe and uncontrolled cases. Systemic therapeutic options may include cyclosporine (Cordoro, 2008; Mahe et al., 2001) , systemic retinoids (Davis and Krafchik, 1993; Rosinska et al., 1988) and methotrexate (Collin et al., 2006; Kumar et al., 1994) . Limited resources and studies are available to assess appropriately the efficacy and safety of these treatments in childhood psoriasis. We have not tried such modalities in our series and no further comments can be made.
Biologics
The biologic therapy namely Tumor Necrosis Factor-alpha (TNF-alpha) blockers like etanercept and infliximab has been used recently in pediatric auto immune diseases like rheumatoid arthritis, TNF-a receptor 1-associated periodic syndrome without fever (TRAPS), juvenile idiopathic arthritis and crohn's disease. Safety and efficacy of etanercept therapy have been recognized in juvenile rheumatoid arthritis patients (Lovell et al., 2008) . In a placebo-controlled randomized double-blind trial, 211 children with plaque psoriasis were treated with once-weekly subcutaneous injections of etanercept (0.8 mg/kg), with a maximum dose of 50 mg. At week 12, 27% of patients treated with etanercept reached PASI 90, in contrast to 7% of patients treated with placebo (Paller et al., 2008) . Further reports manifest the positive response of etanercept (Safa et al., 2007; Papoutsaki et al., 2006) . In one case report one child with psoriasis was successfully treated with Infliximab after failure of etanercept (Farnsworth et al., 2005) . We did not use these drugs in our patients at this stage. But we stress that these drugs cannot be used frequently until more data are available about the risk-benefit ratio of these treatments in childhood psoriasis. With future studies proper positioning of biologics in the therapeutic ladder of psoriasis in children might be possible.
Conclusion
With evaluation of our series of children with psoriasis we conclude that childhood psoriasis is more common in females with plaque type psoriasis being the most common type. Topical therapy is the mainstay treatment for localized disease. At present, NB-UVB phototherapy is a safe and effective modality for moderately severe cases particularly in children with poor response to topical therapeutic protocols. Systemic therapy and biologics should be reserved for severe and uncontrolled cases. More clinical studies are required to define the safety levels of systemic therapies and biologic treatments to properly define their position in the therapeutic ladder of childhood psoriasis.
